proliferative diabetic retinopathy

Novel therapies could stem burden of diabetic eye diseaseA better understanding of the pathophysiologic mechanisms of diabetes has resulted in improved control of its local and systemic comorbidities. Further developments are needed, however, considering the growing number of diabetic patients and who are at risk for late-stage diabetic eye disease.
New strategies to assess the risk of diabetes-related vision lossA colleague recently told me that eye doctors should “stay within the lines” of traditional eye care because we barely have enough time as it is to do our jobs. My response was that today more than half of our adult patients have either diabetes or prediabetes, so our job now requires we go ”outside the lines” to avoid the leading cause of preventable blindness.
Choosing the right treatment for proliferative diabetic retinopathy
Choosing the right treatment for proliferative diabetic retinopathyRetina specialists who are Diabetic Retinopathy Clinical Research Network investigators offer views on whether laser panretinal photocoagulation or anti-VEGF therapy deserves consideration as first-line treatment for proliferative diabetic retinopathy.
Study: Fluocinolone acetonide 0.2 µg/day reduced DR progressionTreatment with fluocinolone acetonide 0.2 µg/day significantly reduced progression to proliferative diabetic retinopathy (PDR) in patients who were part of the FAME trials1,2 and had visual acuity loss due to diabetic macular edema (DME), according to Charles C. Wykoff, MD, PhD.
DRCRnet Protocol S results provide evidence for retinopathy advanceResults from the Diabetic Retinopathy Clinical Research Network Protocol S provide evidence for the first major advance in the treatment of proliferative diabetic retinopathy (PDR) in more than 40 years, said Jeffrey Gross, MD.
Ranibizumab proves instrumental for DME patients in RIDE, RISE trialsRanibizumab provided improvements in visual acuity and DR that were stable over the long term when the drug was administered on an as-needed regimen to patients with diabetic macular edema in the RIDE and RISE trials.
Ophthalmologists’ role key to mitigating burden of diabetic eye diseasePreserving vision in patients with diabetes requires ophthalmologists to be aware of the importance of reinforcing preventive strategies, maintaining communication with internists/diabetologists, and keeping up to date with current treatment approaches.
Diabetes nation: addressing an epidemicDuring the American Academy of Optometry's Academy 2014, presenters shared how optometrists can help halt the diabetes epidemic and combat associated ocular complications.
Trial evaluates ranibizumab for vitreous hemorrhageA study suggests little likelihood of a clinically important difference between ranibizumab and saline on the rate of vitrectomy in eyes with vitreous hemorrhage from PDR.